(CS-140) Post-Acute Care of Stalled Pressure Injuries with Placental Allografts

Allyn Forsyth, PhD – Senior Director, Clinical Evidence, Medical Affairs, MIMEDX Group Inc; Dorothy Kurtz Phelan, DPM, D.BFAS, FACFAS – Senior Medical Science Liaison, Medical Affairs, MIMEDX Group Inc; Martha Kelso, RN, CHWS, DAPWCA, HBOT – Founder and Chief Regulatory Officer, Wound Care Plus, LLC

Introduction:

Pressure injuries (PIs) affect over 2.5 million U.S. patients annually and impose significant morbidity, mortality, and economic burden. Advanced-stage PIs often stall in post-acute care settings, where access to specialized wound care is limited. Here we report outcomes in a patients with a stalled stage-3 PI treated using placental allografts adjunctively to rigorous standard of care by mobile wound care specialists.

Methods: Individualized treatment plans included diagnostic monitoring (nutrition, perfusion, bioburden), caregiver education, and standard interventions (debridement, offloading, compression). When wounds failed to progress, lyophilized human amnion/chorion membrane (LHACM) allografts were applied weekly or biweekly until closure. Wound size and characteristics were tracked longitudinally.

Results:

Subject achieved complete closure following escalation to placental allografts after prolonged non-healing under standard care. No recurrences were observed during follow-up. These findings align with prior evidence supporting LHACM efficacy in chronic wounds.

Discussion:

Mobile wound care specialists combined with placental allografts may provide an effective strategy for closing stalled PIs in post-acute settings, improving outcomes and reducing complications in high-risk populations. Controlled studies are needed to confirm effectiveness and cost-benefit.